Oslo, 27 May 2025: Reference is made to the notice of the annual general meeting
of Circio Holding ASA (the "Company") published on 15 May 2025 and the annual
general meeting ("AGM") to be held on Thursday 5 June 2025 at 10:00 hours
(CEST).

The board of directors has resolved to withdraw the proposals under agenda item
10 "Reverse Share Split" and agenda item 11 "Share Capital Decrease".
Consequently, agenda item 10 and agenda item 11 will not be subject to voting at
the AGM.

In addition, the board of directors proposes that the previously proposed board
authorizations in agenda items 12 "General board authorization to increase the
share capital" and agenda item 13 "Board authorization to increase the share
capital in connection with share incentive arrangements and grant of restricted
stock units to the board of directors as remuneration" are adjusted to reflect
the withdrawal of the reverse share split and the share capital decrease.

For agenda item 12, the board of directors proposes that it is granted an
authorization to increase the Company's share capital by up to either 40%
(agenda item 12.1), 30% (agenda item 12.2), or 20% (agenda item 12.3) of the
Company's share capital as of the date of the general meeting.

For agenda item 13, the board of directors proposes that it is granted an
authorisation to increase the Company's share capital by up to 10% of the
Company's share capital as at the date of the general meeting.

An updated AGM registration and proxy form is attached to this announcement and
is available for advance voting through the logging on to VPS Investor Services,
by following link on the Company's webpage https://www.circio.com/en/annual
-general-meeting-2025/. Please note that any advance votes cast on the items
under agenda item 10 and agenda item 11 will be considered void. Any advance
votes cast on agenda item 12 and 13 can be changed up until the applicable
voting deadlines as given in the notice.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.